Triazolopyrimidines identified as reversible myeloperoxidase inhibitors. Issue 11 (26th October 2017)

• Record Type: Journal Article
• Authors: Duclos, Franck; Abell, Lynn M.; Harden, David G.; Pike, Kristen; Nowak, Kimberly; Locke, Gregory A.; Duke, Gerald J.; Liu, Xiaoqin; Fernando, Gayani; Shaw, Scott A.; Vokits, Benjamin P.; Wurtz, Nicholas R.; Viet, Andrew; Valente, Meriah N.; Stachura, Sylwia; Sleph, Paul; Khan, Javed A.; Gao, Ji; Dongre, Ashok R.; Zhao, Lei; Wexler, Ruth R.; Gordon, David A.; Kick, Ellen K.
• Is Part Of: MedChemComm. Volume 8:Issue 11(2017)
• Page Start: 2093
• Page End: 2099
• Publication Date: 2017-10-26
• Subjects: Pharmaceutical chemistry -- Periodicals; 615.19
• DOI: 10.1039/c7md00268h
• Languages: English
• ISSNs: 2040-2503

Abstract

Abstract : A novel myeloperoxidase inhibitor, 7-benzylether triazolopyrimidine was discovered which reversibly inhibits enzyme activity and shows pharmacodynamic effects in mouse models. Abstract : Myeloperoxidase, a mammalian peroxidase involved in the immune system as an anti-microbial first responder, can produce hypochlorous acid in response to invading pathogens. Myeloperoxidase has been implicated in several chronic pathological diseases due to the chronic production of hypochlorous acid, as well as other reactive radical species. A high throughput screen and triaging protocol was developed to identify a reversible inhibitor of myeloperoxidase toward the potential treatment of chronic diseases such as atherosclerosis. The identification and characterization of a reversible myeloperoxidase inhibitor, 7-(benzyloxy)-3 H -[1, 2, 3]triazolo[4, 5- d ]pyrimidin-5-amine is described.